Upstream / Downstream

pathwayImage

Explore pathways related to this product.

Antibody Guarantee

CST Antibody Performance Guarantee

LEARN MORE  

To get local purchase information on this product, click here

Questions?

Find answers on our FAQs page.

ANSWERS  

Visit PhosphoSitePlus®

PTM information and tools available.

LEARN MORE

REACTIVITY SENSITIVITY MW (kDa) SOURCE
Endogenous Rabbit

Product Usage Information

Storage: Supplied in PBS (pH 7.2), less than 0.1% sodium azide and 2 mg/ml BSA. Store at 4°C. Do not aliquot the antibody. Protect from light. Do not freeze.

Specificity / Sensitivity

Phospho-FLT3 (Tyr591) Antibody detects endogenous FLT3 only when phosphorylated at tyrosine 591. The antibody does not cross-react with other FLT family members. It may cross-react with some tyrosine phosphorylated proteins.

(US Patent No. 7,183,385 and foreign equivalents assigned to Cell Signaling Technology, Inc.)


Source / Purification

Polyclonal antibodies are produced by immunizing animals with a synthetic phosphopeptide corresponding to residues surrounding Tyr591 of human FLT3. Antibodies are purified by protein A and peptide affinity chromatography.The antibody was conjugated to Alexa Fluor®488 under optimal conditions with an F/P ratio of 2-5.

FMS-related tyrosine kinase 3 (FLT3, also called Flk2), is a member of the type III receptor tyrosine kinase family, which includes c-Kit, PDGFR and M-CSF receptors. FLT3 is expressed on early hematopoietic progenitor cells and supports growth and differentiation within the hematopoietic system (1,2). FLT3 is activated after binding with its ligand FL, which results in a cascade of tyrosine autophosphorylation and tyrosine phosphorylation of downstream targets (3). The p85 subunit of PI3 kinase, SHP2, GRB2 and Shc are associated with FLT3 after FL stimulation (4-6). Tyr589/591 is located in the juxtamembrane region of FLT3 and may play an important role in regulation of FLT3 tyrosine kinase activity. Somatic mutations of FLT3 consisting of internal tandem duplications (ITDs) occur in 20% of patients with acute myeloid leukemia (7).


1.  Shurin, M.R. et al. (1998) Cytokine Growth Factor Rev 9, 37-48.

2.  Naoe, T. et al. (2001) Cancer Chemother Pharmacol 48 Suppl 1, S27-30.

3.  Namikawa, R. et al. (1996) Stem Cells 14, 388-95.

4.  Beslu, N. et al. (1996) J Biol Chem 271, 20075-81.

5.  Zhang, S. and Broxmeyer, H.E. (2000) Biochem Biophys Res Commun 277, 195-9.

6.  Zhang, S. et al. (1999) J Leukoc Biol 65, 372-80.

7.  Mizuki, M. et al. (2000) Blood 96, 3907-14.


Entrez-Gene Id 2322
Swiss-Prot Acc. P36888


For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.
The Alexa Fluor® dye antibody conjugates in this product are sold under license from Life Technologies Corporation for research use only, except for use in combination with DNA microarrays. The Alexa Fluor® dyes (except for Alexa Fluor® 430 dye) are covered by pending and issued patents. Alexa Fluor® is a registered trademark of Molecular Probes, Inc.